Bharat Immunologicals Current Valuation

The Macroaxis Fundamental Analysis lookup allows users to check a given indicator for any equity or select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also Equity Screeners to view more equity screening tools
Symbol
Refresh

Current Valuation Analysis

Enterprise Value is a firm valuation proxy that approximates current market value of a company. It is typically used to determine takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that company has on its balance sheet. When takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Bharat Immunologicals 
Enterprise Value 
 = 
Market Cap + Debt 
-  
Cash 
 = 
862.5 M

About Current Valuation

Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Compare to competition
In accordance with recently published financial statements Bharat Immunologicals Biologicals Corp Ltd has Current Valuation of 862.5 M. This is much higher than that of the sector, and significantly higher than that of Current Valuation industry, The Current Valuation for all stocks is over 1000% lower than the firm.

Peer Comparison

Bharat Immunologicals Current Valuation Comparison
Bharat Immunologicals is currently under evaluation in current valuation category among related companies.

Did you try this?

Run Price Exposure Probability Now
   

Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
Hide  View All  Next  Launch Price Exposure Probability
Return On Equity(11.52) %
Return On Asset(1.69) %
Profit Margin(4.18) %
Operating Margin(5.13) %
Current Valuation862.5 M
Shares Outstanding43.18 M
Price to Earning65.75 times
Price to Book2.50 times
Price to Sales0.66 times
Revenue1.28 B
Gross Profit119 M
EBITDA(56.51 M)
Net Income(53.46 M)
Cash and Equivalents152.27 M
Cash per Share3.55 times
Total Debt177.56 M
Debt to Equity0.50 times
Current Ratio1.69 times
Book Value Per Share8.21 times
Earnings Per Share(1.24) times
Market Capitalization844.17 M
Z Score2.4